Tag Archives: Coverage

Coverage Initiated on Miner Focused on Reviving Idaho Mine

A Paradigm Capital report presented the highlights of this brownfields story. In a Nov. 21, 2018, research note, Analyst Don Blyth reported that Paradigm Capital initiated coverage on Revival Gold Inc. (RVG:TSX.V), an advanced-stage explorer/developer, with a Speculative Buy rating and a CA$1.85 price target. In comparison, the stock is trading today at around CA$0.68 per share. The company intends ...

Read More »

Coverage Initiated on Miner Focused on Reviving Idaho Mine

A Paradigm Capital report presented the highlights of this brownfields story. In a Nov. 21, 2018, research note, Analyst Don Blyth reported that Paradigm Capital initiated coverage on Revival Gold Inc. (RVG:TSX.V), an advanced-stage explorer/developer, with a Speculative Buy rating and a CA$1.85 price target. In comparison, the stock is trading today at around CA$0.68 per share. The company intends ...

Read More »

Coverage Initiated on Developer of Targeted Gene Therapies for Cancer

A LifeSci Capital report highlighted the advantages of this biotech story’s lead candidate targeting bladder cancer. In an Oct. 30, 2018, research note, analyst Sam Slutsky reported that LifeSci Capital initiated coverage on Anchiano Therapeutics Ltd. (ANCN:TLV), a clinical-stage biotechnology company developing gene therapy-based drugs for the treatment of cancer. Slutsky outlined the factors that make this company an attractive ...

Read More »

Coverage Initiated on Developer of Targeted Gene Therapies for Cancer

A LifeSci Capital report highlighted the advantages of this biotech story’s lead candidate targeting bladder cancer. In an Oct. 30, 2018, research note, analyst Sam Slutsky reported that LifeSci Capital initiated coverage on Anchiano Therapeutics Ltd. (ANCN:TLV), a clinical-stage biotechnology company developing gene therapy-based drugs for the treatment of cancer. Slutsky outlined the factors that make this company an attractive ...

Read More »

Biotechs Preliminary Immunotherapy Data Positive, Earns Coverage in Medical Journal

An H.C. Wainwright & Co. report reviewed both the results and an “unusual” highlight from this firm’s trial in head-and-neck cancer. In a Sept. 24 research note, analyst Ram Selvaraju reported that three days earlier, Clinical Cancer Research published “positive” preliminary clinical data on Inovio Pharmaceuticals Inc.’s (INO:NASDAQ) MEDI0457 in head-and-neck cancer. “The published data give us hope that the ...

Read More »

Biotechs Preliminary Immunotherapy Data Positive; Earns Coverage in Medical Journal

An H.C. Wainwright & Co. report reviewed both the results and an “unusual” highlight from this firm’s trial in head-and-neck cancer. In a Sept. 24 research note, analyst Ram Selvaraju reported that three days earlier, Clinical Cancer Research published “positive” preliminary clinical data on Inovio Pharmaceuticals Inc.’s (INO:NASDAQ) MEDI0457 in head-and-neck cancer. “The published data give us hope that the ...

Read More »